UNSPSC 51363202: Apronal or apronalide

This classification denotes a urea analog with the molecular formula C9H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V18J24E25E, chemically known as 4-pentenamide, n-(aminocarbonyl)-2-(1-methylethyl)- but generally known as apronal, which bears US NIH Compound Identifier 10715. European Medicines Agency schedules Apronal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12929MIG. World Health Organization schedules apronal in its Anatomical Therapeutic Chemical (ATC) Classification.

SMILES: O=C(NC(=O)N)C(C(C)C)CC=C.

UNSPSC 51363202 Apronal or apronalide is a Commodity code that does not align with the state and local procurement activity presently tagged under it. The recent opportunities solicited under this code involve naloxone (a controlled opioid antagonist), generic pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription programs—none of which are apronal or apronalide, which are veterinary anesthetic agents. The mismatch suggests either a data-entry error in the state and local opportunity database or a significant drift between the code's nominal scope and current purchasing practice. State and local governments show limited recent activity specifically for apronal or apronalide itself.

The three recent opportunities logged under this code reflect broader pharmaceutical procurement by state health agencies, county health departments, and cooperative purchasing alliances. Seminole County, Florida (via IFB60459723LAS, due July 26, 2023) solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB; the Texas Health and Human Services Commission (via RFI HHS0017013, April 2026) issued a Request for Information to gather vendor capability data on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (via RFP S1070000015802, due March 26, 2026) sought multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota, Oregon, and other MMCAP member jurisdictions. Geographic spread includes Florida, Texas, and the Upper Midwest. Vendors pursuing apronal or apronalide specifically should verify that opportunities are correctly tagged before committing bid resources, as current database entries do not reflect the product category.